Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.66 |
| ▸ | HSP90AA1 | P07900 | 9/20 | 0.59 |
| ▸ | HSP90AB1 | P08238 | 9/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30532617 | 1.00 | HDAC6 (0.66) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL25547980 | 0.89 | HDAC6 (0.69) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL21977307 | 0.89 | HDAC6 (0.69) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL21977339 | 0.87 | CDK1 (0.57) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL12857150 | 0.86 | HDAC6 (0.70) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL6272417 | 0.86 | ALDH1A1 (0.66) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL5461215 | 0.86 | HDAC6 (0.60) | HDAC6HDAC1HDAC4HDAC2HDAC3 | |
| SCHEMBL3389693 | 0.84 | HDAC6 (0.63) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL22533970 | 0.83 | HDAC6 (0.65) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 | |
| SCHEMBL3389606 | 0.83 | HSP90AB1 (0.71) | HDAC6HDAC1HDAC4HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11986480-B2 | Heterocyclic compound | TOHOKU UNIVERSITY (JP) | 2024-05-21 | — | — | US | disclosed |
| CN-116570565-A | Artificial autophagy targeting chimeric and preparation method and application thereof | 四川大学 | 2023-08-11 | — | — | CN | disclosed |
| US-20200163970-A1 | HETEROCYCLIC COMPOUND | TOHOKU UNIVERSITY (JP) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163970-A1 | HETEROCYCLIC COMPOUND | SQSTM1, BECN1, ATG7 | HDAC6 17/4885HDAC1 131/4885HDAC4 342/4885 |
| US-11986480-B2 | Heterocyclic compound | SQSTM1, BECN1, ATG7 | HDAC6 17/4885HDAC1 131/4885HDAC4 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.